■生物疗法对牛皮癣有效,但是病人的反应各不相同,通常需要转换或停止治疗。
■在沙特阿拉伯转诊三级中心确定医生的生物疗法处方模式,并评估开始治疗后生物持续的可能性。
我们对2013年10月至2022年7月在达曼开始治疗的未治疗成人银屑病患者进行了回顾性研究。描述性统计和Kaplan-Meier分析评估了6、12、24和36个月的治疗持久性。
■共有151名患者接受了阿达木单抗(n=89),依那西普(n=17),利安珠单抗(n=30),ustekinumab(n=14),和ixekizumab(n=1)。6个月时,所有疗法均表现出100%的持久性.12个月时,ustekinumab的持久性最高(100%),依那西普的持久性最低(88.2%).24个月时,ustekinumab保持100%的持久性,其次是risankizumab(96.6%),阿达木单抗(94.3%),和依那西普(76.4%)。36个月时,risankizumab的持久性最高(96.6%),其次是阿达木单抗(83.1%),ustekinumab(78%),和依那西普(70.6%)。停药的最常见原因是缺乏有效性和不能容忍。
■这项研究表明,用新疗法改变了银屑病的治疗模式。Risankizumab表现出很高的长期持久性,而依那西普和ustekinumab的持久性下降,建议不断发展的治疗考虑。
UNASSIGNED: Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.
UNASSIGNED: To identify physicians\' prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation.
UNASSIGNED: We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months.
UNASSIGNED: A total of 151 patients received adalimumab (n = 89),
etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for
etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and
etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and
etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability.
UNASSIGNED: This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while
etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.